Expression of costimulatory molecule B7-H3 in human osteosarcoma and its clinical significance

王　玲; 刘　磊; 陈　伟

doi:10.3969/j.issn.1007-3969.2015.10.002

您当前的位置：

首页 >

文章列表页 >

Expression of costimulatory molecule B7-H3 in human osteosarcoma and its clinical significance

更新时间：2025-12-31

- Expression of costimulatory molecule B7-H3 in human osteosarcoma and its clinical significance
- China Oncology Vol. 25, Issue 10, Pages: 768-773(2015)
- 作者机构：
  
  1. 河北医科大学第三医院骨科研究所,河北,石家庄,050011
  2. 河北医科大学第四医院肿瘤研究所,河北,石家庄,050011
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.10.002
  CLC：
- Published Online：17 December 2015，
  
  Published：17 December 2015
- 稿件说明：
移动端阅览
王　玲,刘　磊,陈　伟,等. 共刺激分子B7-H3在骨肉瘤组织中的表达及临床意义[J]. 中国癌症杂志, 2015, 25(10): 768-773.

王　玲, 刘　磊, 陈　伟. Expression of costimulatory molecule B7-H3 in human osteosarcoma and its clinical significance[J]. China Oncology, 2015, 25(10): 768-773.
王　玲,刘　磊,陈　伟,等. 共刺激分子B7-H3在骨肉瘤组织中的表达及临床意义[J]. 中国癌症杂志, 2015, 25(10): 768-773. DOI： 10.3969/j.issn.1007-3969.2015.10.002.

王　玲, 刘　磊, 陈　伟. Expression of costimulatory molecule B7-H3 in human osteosarcoma and its clinical significance[J]. China Oncology, 2015, 25(10): 768-773. DOI： 10.3969/j.issn.1007-3969.2015.10.002.

摘要

背景与目的：B7-H3是近年来新发现的协同刺激分子B7家族成员，但目前其在骨肿瘤中的表达及作用机制尚不明确。该研究旨在通过检测人骨肉瘤中B7-H3分子的表达，分析其与患者临床病理因素以及术后生存时间之间的关系。方法：采用免疫组织化学法检测61例人骨肉瘤组织、对应癌旁组织及良性骨肿瘤组织中B7-H3分子的表达以及肿瘤浸润T淋巴细胞的浸润程度。结果：骨肉瘤组织中B7-H3分子表达的阳性率为91.8(56/61)，而B7-H3在癌旁及骨纤维结构发育不良组织中几乎不表达。B7-H3分子在骨软骨瘤中表达率为56.8%，但染色强度明显弱于骨肉瘤组织。B7-H3的表达与患者的Ennecking分期、是否发生肺转移之间的差异有统计学意义(P0.05)，与肿瘤组织中CD8

T淋巴细胞浸润程度呈负相关(P0.05)，与患者预后呈负相关(P0.05)。结论：B7-H3在人骨肉瘤中组织异常高表达，并与肿瘤的进展、患者的预后密切相关；B7-H3可能参与了骨肉瘤微环境中的CD8

T细胞功能的调节，促使肿瘤细胞逃避免疫监视。

Abstract

Background and purpose: B7-H3 is a newly identified member of the B7-family of co-stimulatory molecule

and however

its exact role in human osteosarcoma is still unclear. The purpose of this study was to examine the expression of B7-H3 in osteosarcoma tissues and to investigate its correlations with clinicopathological factors and overall survival in patients with osteosarcoma. Methods: The expression of B7-H3 and the intensity of tumorinfiltrating T lymphocytes (TILs) in pathologic specimens of osteosarcoma

osteochondroma and bone fibrous dysplasia tissues were evaluated by immunohistochemical assay. Results: The expression rate of B7-H3 was 91.8% (56/61) in osteosarcoma lesions

while B7-H3 was barely expressed in adjacent nor

mal tissues and bone fibrous dysplasia tissues. The intensity of B7-H3 expression in osteochondroma was 56.8%

which was significantly decreased compared with osteosarcoma tissues. Tumor B7-H3 expression was associated with Ennecking stage and pulmonary metastasis

while inversely correlated with the number of tumor-infiltrating CD8

T cells (P0.05). Moreover

patients with high tumor B7-H3 levels had a significantly shorter survival time and recurrence time than patients with low tumor B7-H3 levels (P0.05). Conclusion: B7-H3 is overexpressed in human osteosarcoma tissues

and B7-H3 expression is highly correlated with tumor development and overall patients’ prognosis. Moreover

overexpression of B7-H3 in tissues can reflect CD8

T cell infiltration and may help tumor cells avoid immune surveillance.

关键词

Keywords

references

Views

1541

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Expression and clinical significance of PAK5 protein expression in osteosarcoma

Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas

Expression of MMR in 515 cases of endometrioid adenocarcinoma and its correlation with clinicopathological features

Clinicopathological characteristics and prognostic analysis of medullary thyroid carcinoma in children and adolescents

Related Author

田聪

汤丽娜

林峰

沈赞

陈杰

姚阳

闵大六

Lijun CHEN

Related Institution

上海交通大学附属第六人民医院病理科

上海交通大学附属第六人民医院肿瘤内科

苏州大学医学部研究生院

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Pathology, Shengjing Hospital of China Medical University

AI问答

⁰